​
​

Dianthus Therapeutics (DNTH) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

DNTH Stock Forecast

Dianthus Therapeutics stock forecast is as follows: an average price target of $51.50 (represents a 154.07% upside from DNTH’s last price of $20.27) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

DNTH Price Target

The average price target for Dianthus Therapeutics (DNTH) is $51.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $51.00. This represents a potential 154.07% upside from DNTH's last price of $20.27.

DNTH Analyst Ratings

Buy

According to 7 Wall Street analysts, Dianthus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DNTH stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Dianthus Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 11, 2024Leland GershellOppenheimer$52.00$28.7381.03%156.54%
Apr 18, 2024Steven SeedhouseRaymond James$51.00$24.15111.18%151.60%
Row per page
Go to

The latest Dianthus Therapeutics stock forecast, released on Nov 11, 2024 by Leland Gershell from Oppenheimer, set a price target of $52.00, which represents a 81.03% increase from the stock price at the time of the forecast ($28.73), and a 156.54% increase from DNTH last price ($20.27).

Dianthus Therapeutics Price Target by Period

1M3M12M
# Anlaysts112
Avg Price Target$52.00$52.00$51.50
Last Closing Price$20.27$20.27$20.27
Upside/Downside156.54%156.54%154.07%

In the current month, the average price target of Dianthus Therapeutics stock is $52.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 156.54% increase as opposed to Dianthus Therapeutics's last price of $20.27. This month's average price target is down 0.00% compared to last quarter, and up 0.97% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 11, 2024OppenheimerOutperformOutperformHold
Oct 04, 2024GuggenheimBuyBuyHold
Oct 02, 2024Oppenheimer-OutperformInitialise
Sep 26, 2024H.C. WainwrightUnderperformUnderperformHold
Sep 26, 2024WedbushBuyBuyHold
Aug 12, 2024WedbushBuyBuyHold
Aug 12, 2024H.C. WainwrightUnderperformUnderperformHold
Jun 27, 2024Cantor Fitzgerald-OverweightInitialise
May 16, 2024H.C. Wainwright-BuyInitialise
Apr 18, 2024Raymond JamesOutperformOutperformHold
Row per page
Go to

Dianthus Therapeutics's last stock rating was published by Oppenheimer on Nov 11, 2024. The company gave DNTH a "Outperform" rating, the same as its previous rate.

Dianthus Therapeutics Financial Forecast

Dianthus Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
Revenue---------$924.00K
Avg Forecast$778.67K$778.67K$778.67K$762.00K$949.63K$741.14K$368.86K$464.25K$548.50K$250.00K
High Forecast$1.16M$1.16M$1.16M$1.09M$1.47M$1.10M$548.23K$690.01K$728.83K$371.57K
Low Forecast$488.00K$488.00K$488.00K$451.18K$630.82K$464.48K$231.17K$290.95K$225.41K$156.68K
# Analysts1114631131
Surprise %---------3.70%

Dianthus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $548.50K, with a low forecast of $225.41K, and a high forecast of $728.83K. DNTH's average Quarter revenue forecast represents a -40.64% decrease compared to the company's last Quarter revenue of $924.00K (Sep 23).

Dianthus Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts1114631131
EBITDA---------$-15.74M
Avg Forecast$-155.73K$-155.73K$-155.73K$-152.40K$-189.92K$-148.23K$-73.77K$-92.85K$-109.70K$-50.00K
High Forecast$-97.60K$-97.60K$-97.60K$-90.24K$-126.16K$-92.90K$-46.23K$-58.19K$-45.08K$-31.34K
Low Forecast$-231.47K$-231.47K$-231.47K$-217.57K$-294.38K$-220.31K$-109.65K$-138.00K$-145.76K$-74.31K
Surprise %---------314.87%

undefined analysts predict DNTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Dianthus Therapeutics's previous annual EBITDA (undefined) of $NaN.

Dianthus Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts1114631131
Net Income---------$-14.76M
Avg Forecast$-31.50M$-32.07M$-31.90M$-30.24M$-29.00M$-20.36M$-18.67M$-15.00M$-32.18M$-19.17M
High Forecast$-16.21M$-16.51M$-16.42M$-20.60M$-19.79M$-10.48M$-9.61M$-7.72M$-30.15M$-9.87M
Low Forecast$-51.41M$-52.34M$-52.06M$-40.21M$-38.89M$-33.23M$-30.47M$-24.48M$-37.69M$-31.29M
Surprise %---------0.77%

Dianthus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DNTH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Dianthus Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts1114631131
SG&A---------$8.72M
Avg Forecast$1.68M$1.68M$1.68M$1.65M$2.05M$1.60M$796.86K$1.00M$1.18M$540.08K
High Forecast$2.50M$2.50M$2.50M$2.35M$3.18M$2.38M$1.18M$1.49M$1.57M$802.73K
Low Forecast$1.05M$1.05M$1.05M$974.71K$1.36M$1.00M$499.40K$628.55K$486.96K$338.48K
Surprise %---------16.15%

Dianthus Therapeutics's average Quarter SG&A projection for Dec 23 is $1.18M, based on 3 Wall Street analysts, with a range of $486.96K to $1.57M. The forecast indicates a -86.42% fall compared to DNTH last annual SG&A of $8.72M (Sep 23).

Dianthus Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23
# Analysts1114631131
EPS---------$-3.78
Avg Forecast$-0.92$-0.94$-0.93$-0.88$-0.85$-0.59$-0.55$-0.44$-0.94$-0.56
High Forecast$-0.47$-0.48$-0.48$-0.60$-0.58$-0.31$-0.28$-0.23$-0.88$-0.29
Low Forecast$-1.50$-1.53$-1.52$-1.17$-1.14$-0.97$-0.89$-0.71$-1.10$-0.91
Surprise %---------6.75%

According to undefined Wall Street analysts, Dianthus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DNTH previous annual EPS of $NaN (undefined).

DNTH Forecast FAQ

Is Dianthus Therapeutics a good buy?

Yes, according to 7 Wall Street analysts, Dianthus Therapeutics (DNTH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of DNTH's total ratings.

What is DNTH's price target?

Dianthus Therapeutics (DNTH) average price target is $51.5 with a range of $51 to $52, implying a 154.07% from its last price of $20.27. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Dianthus Therapeutics stock go up soon?

According to Wall Street analysts' prediction for DNTH stock, the company can go up by 154.07% (from the last price of $20.27 to the average price target of $51.5), up by 156.54% based on the highest stock price target, and up by 151.60% based on the lowest stock price target.

Can Dianthus Therapeutics stock reach $30?

DNTH's average twelve months analyst stock price target of $51.5 supports the claim that Dianthus Therapeutics can reach $30 in the near future.

What is Dianthus Therapeutics's current price target trend?

1 Wall Street analyst forecast a $52 price target for Dianthus Therapeutics (DNTH) this month, up 156.54% from its last price of $20.27. Compared to the last 3 and 12 months, the average price target increased by 156.54% and increased by 154.07%, respectively.

What are Dianthus Therapeutics's analysts' financial forecasts?

Dianthus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.52M (high $3.81M, low $1.62M), average EBITDA is $-505K (high $-323K, low $-762K), average net income is $-83.018M (high $-47.592M, low $-127M), average SG&A $5.45M (high $8.23M, low $3.49M), and average EPS is $-2.425 (high $-1.39, low $-3.711). DNTH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.1M (high $4.56M, low $1.92M), average EBITDA is $-620K (high $-383K, low $-912K), average net income is $-126M (high $-69.742M, low $-196M), average SG&A $6.69M (high $9.85M, low $4.14M), and average EPS is $-3.672 (high $-2.037, low $-5.726).

Did the DNTH's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Sep 2023), Dianthus Therapeutics's revenue was $924K, beating the average analysts' forecast of $250K by 269.60%. The company's EBITDA was $-15.743M, beating the average prediction of $-49.999K by 31386.63%. Dianthus Therapeutics's net income was $-14.763M, missing the average estimation of $-19.173M by -23.00%. The company's SG&A was $8.72M, beating the average forecast of $540.08K by 1515.12%. Lastly, the company's EPS was $-3.78, beating the average prediction of $-0.56 by 575.00%